Calithera Bio reports updated results from phase 1 study of telaglenastat (CB-839)
Calithera announced updated data from a Phase 1 study of the glutaminase inhibitor telaglenastat in combination with cabozantinib in patients with advanced RCC. In preclinical studies, telaglenastat produced synergistic antitumor effects when used in combination with standard-of-care RCC therapies. February 16, 2019